CRB-913 was safe and well-tolerated across all doses studied Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants A placebo-adjusted mean weight loss of ...
Recent advances in immunology have underscored the pivotal role of the transcription factor RORγt in orchestrating the differentiation of Th17 cells and the consequent production of proinflammatory ...
MENLO PARK, Calif., January 16, 2026--(BUSINESS WIRE)--OrsoBio, Inc. ("OrsoBio" or "the Company"), a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic ...
NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced the Company’s plan to release ...
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabant SAD/MAD Phase 1 trial scheduled ...
NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the initiation of the ...
When eating, the body converts extra calories, especially from carbs, sugar, fats, and alcohol, into triglycerides. Triglycerides are a form of fat or lipid, which the body stores away into its fat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results